glp-1 and gip dual agonist Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data TrimRX | GLP-1 vs GIP:

As with any medication purchase, verify pharmacy credentials and discuss with your prescriber before switching sources

In the isolated perfused pig pancreas, GLP-1 dose-dependently stimulates the secretion of somatostatin [475] which is a potent suppressor of glucagon secretion [584]

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus

GLP-1 Receptor Expression Within the Human Heart

Other important contributing factors are eating disorders and depression, which are more common in patients with T1D compared to the overall population ( Figure 1 Obesity increases the risk of obesity-related as well as diabetes-related complications in patients with T1D, including micro- and macrovascular complications, various types of cancer, and overall mortality ( Figure 1 )

What are the side effects